Captix Biomedical Pty Ltd is a pioneering Australian company developing innovative, implantable, medical technologies to optimise the therapeutic outcomes of cell therapies. Captixbio’s IMITA™ device is a cell protection and delivery technology intended to transform the current cell therapy paradigm for the treatment of Type 1 diabetes. Our team is dedicated to transforming the lives of people living with Type 1 diabetes around the world.